At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Articles|January 1, 1999
- ONCOLOGY Vol 13 No 1
- Volume 13
- Issue 1
Varian Creates Patient Education Web Site
Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments.
Advertisement
Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments. The site includes information from the National Cancer Institute and leading cancer treatment centers. Varians cancer patient education web site is located at
Articles in this issue
almost 28 years ago
Follow-up Essential for Positive Home HIV Test Resultsalmost 28 years ago
FDA Treads Delicate Line Between Safety and Speedalmost 28 years ago
Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Womenalmost 28 years ago
Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsyalmost 28 years ago
Sentinel Lymph Node Mapping in Breast Canceralmost 28 years ago
Komen Foundation Receives Grant to Develop New Breast Imaging Technologyalmost 28 years ago
New Imaging Agent Seems to Enhance Detection of Metastatic Breast Canceralmost 28 years ago
Aspirin Decreases Genetic Mutations Associated With Inherited Colon CancerAdvertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5